Intracellular dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) has been proposed to alter endosomal acidification. The most widely studied consequence of this defect has been alterations in the biochemical properties of cystic fibrosis (CF) respiratory mucus glycoproteins. However, studies confirming the existence of mucous processing defects in CF have been hindered by the lack of in vivo animal models by which to test these hypotheses in the absence of secondary effects of chronic bacterial infection. The human bronchial xenograft model has been useful in evaluating the pathophysiologic differences between CF and non-CF airway epithelium, in the absence of secondary disease effects such as goblet cell hyperplasia. In this study we sought to compare the extent of sulfation within secreted mucus glycoproteins from CF and non-CF human bronchial xenografts. Cumulative results of xenografts generated from 13 independent CF tissue samples demonstrated a statistically significant higher level of sulfation (1.7+0.18, P < 0.026) as compared to non-CF paired controls. Such findings add to the growing body of knowledge that primary defects in sulfation exist in CF respiratory mucin. Correlation of genotype with the extent of mucus sulfation revealed two categories of CF tissues with statistically different mucus sulfation profiles. Results from these studies demonstrated a 2.0±0.15-fold higher level of mucus sulfation produced from xenografts of five defined CF genotypes as compared to non-CF controls (P < 0.004, n = 10). Interestingly, three CF samples for which one mutant allele remained undefined (AF508/unknown or G551D/unknown) demonstrated no statistical difference in the level of sulfation as compared with matched non-CF controls (n = 3). This as yet unknown allele was not identified within a screen for the 26 most common CF mutations. These results provide preliminary evidence for allelic variation within the CF population which may begin to elucidate Introduction Cystic fibrosis (CF)' is a lethal inherited disease caused by abnormalities in epithelial cell function (1, 2) . Patients usually die of respiratory failure due to recurrent and destructive pneumonia. The primary cellular abnormality in the lung is believed to reside in the epithelium of the airways and submucosal glands. Isolation of the gene responsible for CF has provided insight into the molecular basis of the disease (3, 4, 5) . Ongoing progress in the development of effective gene therapies for CF have shown tremendous promise. Despite successes in the ability to transfer the cystic fibrosis transmembrane conductance regulator (CFTR) gene to lungs of animals models (6, 7, 8) and the recent initiative of phase I clinical trials (9, 10, 11) , little is known about the underlying pathophysiologic mechanisms which lead to the development of chronic bacterial infections and unavoidable morbidity of this lung disease. The identification of functionally relevant endpoints for evaluating the effectiveness of gene therapy approaches will aid in the development these therapeutic strategies.
Current hypotheses of the pathophysiologic mechanisms which lead to the unusually thick mucus in CF and chronic Pseudomonas infections are based primarily on the notion that CF respiratory epithelia have defective chloride secretion and elevated sodium absorption (12) (13) (14) (15) . Although the molecular etiology of defective chloride secretion is known to be due to lack of CFTR channel activity, mechanisms by which Na absorption is elevated remain obscure. These alterations in electrolyte transport are thought to create a milieu for bacterial infection by decreasing epithelial fluid secretion which in turn leads to improper hydration of mucus at the epithelial surface, poor mucociliary clearance, and ultimately bacterial colonization ( 1, 16) . In addition to the contribution of electrolyte transport, several other findings have suggested that primary defects in mucous sulfation, sialylation, and/or glycosylation may also contribute to the predisposition of bacterial colonization in the CF lung (17) (18) (19) (20) . These findings suggest, that in addition to apical chloride channel function, CFTR may also play an intracellular role in the processing of glycoproteins. Several studies have supported the notion that CFTR may act as an intracellular chloride channel which regulates anion transport, in conjunction with an ATP driven proton pump, to acidify endosomal compartments (21, 22) . These studies which analyzed the intravesicular pH of golgi compartments have demonstrated a higher pH in CF as compared with non-CF cells. Such defects in golgi pH have been proposed to effect processing of glycoproteins by shifting the pH of this compartment and decreasing the activity of modifying enzymes such as sialyltransferase. Other studies evaluating the effects of defective CFTR on endosomal recycling also support the notion that, in addition to functioning at the apical membrane, CFTR also plays an important role as an intracellular chloride channel (23, 24) .
Previous studies have attempted to evaluate the pathophysiologic contribution CFTR may play as an intracellular chloride channel by analyzing biochemical defects in CF mucus (25) (26) (27) . Two approaches have been traditionally used for this analysis including: (a) the purification and fractionation of mucus from CF and non-CF patients followed by analysis of sulfate, sialic acid, and carbohydrate composition (26, 27) and (b) the purification and fractionation of radiolabeled mucus glycoproteins from CF and non-CF primary nasal or tracheal explants (26, 28) . Because of the complexity of mucus glycoprotein modifications which accompany bacterial infection, disease controls have been used in these studies to minimize the extent of secondary effects. However, due to the unique nature of bacterial infection in CF, secondary changes in mucous biochemistry may likely differ from those found in diseased controls such as chronic bronchitis. Researchers have attempted to address this potential complication by in vitro analysis of nasal and tracheal primary explants which have been removed from the infectious milieu. However, even in the absence of active bacterial infection in primary explants, this experimental design also provides limitations due to the effects of surface epithelial cell remodeling (i.e., goblet cell hyperplasia) which likely persist in culture. Hence, in the absence of a genetic CF model not complicated by bacterial infection or surface airway remodeling, the elucidation of primary defects in mucus remain controversial (29) as indicated by reports which show no abnormalities in the biochemical properties CF mucus (30) .
A uniquely suited model of the human CF and non-CF airway epithelium called human bronchial xenografts has been previously described (7, 31, 33) . In this model system, a fully differentiated epithelium is generated from primary cultures of human bronchial airway epithelial cells seeded onto denuded rat tracheas and transplanted into athymic mice. The ability to reconstitute a fully differentiated epithelium from cultured progenitor cells has allowed for the reconstruction of more pristine CF airways free from secondary effects of bacterial infection. Recently, in vivo electrophysiologic evaluation of this model system has characterized defects in chloride and Na transport which are indicative of those seen in native CF nasal epithelium (32) . Using the human bronchial xenograft model, this report attempts to evaluate the existence of sulfation defects in respiratory mucus glycoproteins from seven different CF genotypes. We compared the sulfation patterns of radiolabeled large molecular weight mucin purified from thirteen CF and non-CF paired human bronchial xenografts. This model system has allowed for a more physiologic evaluation of primary defects in CF mucous biochemistry which are free from secondary effects of airway remodeling due to chronic bacterial infection.
Methods
Generation of CF and non-CF human bronchial primary cell cultures and xenograft airways. Human bronchial xenografts were generated from proximal bronchial tissue harvested from donor (non-CF) and recipient (CF) lungs at the time of transplantation. 13 CF and non-CF paired tissues were analyzed. The CF genotypes analyzed in this study included AF508/AF508 (4); AF508/1717-lG-.A (2); AF508/ 621+l G-*T (2); G542X/G551D (1); AF508/G542X (1); AF508/ unknown (2); and G55lD/unknown (1). The unknown CF alleles are defined as the absence of the following 26 common mutations: G85E, Rl 17H, 621+1G>T, R334W, R347C, R347P, R347H, S492F, Q493R, 1609delCA, A1507, AF508, 1717-lG>A, G542X, S549I, S549N, S549R(A>C), G551D, R553X, R506T, R1162X, S1251N, W1282X, R1283M, R1283K, and N1303K. This panel of mutations has detected 87% of 301 CF chromosomes analyzed from the University of Pennsylvania Molecular Diagnostic laboratory. Of the 13 non-CF patients genotyped, one was heterozygous for the AF508 mutation. Primary cultures of bronchial airway epithelial cells were prepared according to a previous protocol with modifications (31). Modifications in this protocol were adopted to grow cells within a commercially available media (BGEM; Clonetics Corp., San Diego, CA) which allows for the growth of primary cells with basal cell characteristics (i.e., cytokeratin-14 positive by immunocytochemistry, data not shown). We felt that these alteration would provide more homogeneous cultures from CF and non-CF tissues and minimize the secondary effects carried over to primary culture (i.e., the percentage of goblet cells). Additionally, culture medium contained 80 ,g/ml tobramycin, 100 ,g/ml ceftazidime, 100 jig/ ml imepenam/cilastatin, and 2.5 ug/mI amphotericin B to control bacterial and yeast infections. Cultures were propagated by two techniques including explant growth (12-20 d in culture) and proteinase released primary cells (4-7 d in culture). Both techniques provide similar results with respect to the airway reconstitution of xenografts (data not shown). Cultures were harvested by treatment of 0.1% trypsin followed by the addition of 10% FCS/Ham's F12. Cells were pelleted and resuspended in hormonally defined medium for seeding into denuded rat tracheas generated by freeze thawing and irrigation three times. Denuded rat tracheas are devoid of any viable airway epithelium and do not reconstitute an epithelium when transplanted without seeded primary cells (data not shown). Tracheas were ligated to flexible tubing at both ends after seeding of 2 x 106 primary bronchial epithelial cells in 30 IL of hormonally defined medium. Xenografts were implanted in pairs (one non-CF and one CF) subcutaneously in the flanks of male nu/nu Balb/c mice such that the ends of the tubing passed through the skin and were easily accessible for flushing and harvesting of mucus. Xenografts were flushed biweekly with Ham's F12 to remove excess mucus and other secreted proteins. By week 3-4, grafts develop a fully differentiated mucociliary epithelium. Mucin secreted from xenografts was metabolically labeled as described below between 4 and 5 wk after transplantation.
Frequency of goblet cells in CF and non-CF xenografts. The percentage of goblet cells was evaluated by quantitating the number of alcian blue positively stained cells in eight xenografts from four independent genotypes of CF and non-CF paired xenografts. A total of > 5000 airway epithelial cells were screened from each xenograft to determine the frequency of alcian blue positive goblet cells. Statistical comparisons were performed using both paired and unpaired Student's t tests.
Isolation of metabolically labeled mucus glycoprotein from xenografts. Fully differentiated bronchial xenografts were metabolically labeled with both Na2S3504 (25 by irrigation with 1 ml of HPBR and frozen in dry ice. All analyses were performed from paired CF and non-CF xenografts implanted in the same mouse. Crude mucus secretions were purified by two rounds of gel filtration by modifications of a previously described protocol (26, 28) . Xenograft secretions were reduced and denatured by dialysis against 10 mM Tris pH 8.0, 5 mM DTT, and 8 M urea for 24 h followed by fractionation in the same buffer on a sepharose CL-6B column (1 x 60 cm) at a flow rate of 1.5 ml/h. The void volume peaks were pooled, carboxymethylated under nitrogen with 15 mM iodoacetamide pH 9.0 for 45 min at 250C followed by extensive dialysis against 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM PMSF for 48 h. Dialyzed sample was mixed with concentrated stocks of NaAcetate, MgCl2, and PMSF to a final concentration of 0.1 M NaAcetate pH 5.0, 3 mM MgCl2, 1 mM PMSF before digestion with 240 U/ml DNase and 75 U/ml of bovine testicular hyaluronidase (Type VI; Sigma Chemical Co., St.
Louis, MO) for 6 h at 370C. This fraction was then dialyzed against 10 mM Tris pH 8.0, 5 mM DTT, and 8 M urea for 24 h followed by centrifugation in a centricon-30. These concentrated samples (500 Al)
were loaded onto a second gel filtration Sepharose CL-6B column ( 
Results
Expansion ofairway progenitor cell in vitro removes secondary effects ofgoblet cell hyperplasia in CF xenografts. The generation of in vivo bronchial xenograft airways from both CF and non-CF tissues provides the unique opportunity to assess the biochemical differences in secreted mucin from fully differentiated airways. Since, previous studies evaluating secreted mucin in CF airway explants have been hindered by secondary effects of airway remodeling in the presence of bacterial infection, we sought to generate a more pristine CF airway free from goblet cell hyperplasia. We hypothesized that transplantation of bacterial free cultured primary cells would allow for expansion of airway progenitor cells and generation of CF airways with a normal abundance of goblet cells. To this end we evaluated the abundance of goblet cells in CF and non-CF xenografts by alcian blue histochemical staining. These studies demonstrated no statistical differences in the abundance of alcian blue positive goblet cells in four CF (3.2±1.3%) and non-CF (3.6+1.2%) paired xenografts analyzed. These CF airways will provide a more physiologic comparison to non-CF airways by which to base conclusions regarding primary defects in secreted mucin.
Purification and characterization oflarge molecular weight mucus glycoprotein from xenografts. Purified large molecular weight metabolically labeled mucin was analyzed from xenografts generated with 13 paired CF and non-CF bronchial tissues. CF and non-CF-paired xenografts implanted within the same mouse were simultaneously labeled with a mixture of Na2S 3104 and [3H] glucosamine and secretions collected by irrigation. Crude secretions were purified through two rounds of gel filtration which included digestion with hyaluronidase. Additional studies evaluating the resistance of twice gel-filtration purified mucin to Chondroitin ABC lyase and Heparin lyase II demonstrate that Heparin/Heparan sulfate and Chondroitin/ Dermatan sulfate molecules are absent or minor contaminants in these fractions (data not shown). Resistance of purified mucin fractions to these enzymes was determined by the lack of movement of radioactivity from the void volume to the included volume peak using a third gel-filtration column after digestion. Removal of contaminant proteoglycans and N-linked oligosaccharides from mucin samples purified through a single round of gel filtration was documented by two criteria including: (a) the digestion of void volume large molecular weight glycoprotein fractions with hyaluronidase followed by fractionation of a small molecular weight peak on a second gel-filtration column, and (b) the removal of mannose binding lectin (GNA) material from void volume peaks after reduction/carboxymethylation and subsequent elution in the included volume peaks on a second gel-filtration column. Fig. 1 demonstrates the typical gel-filtration elution profile of radiolabeled mucin from a CF and non-CF-paired sample.
The removal contaminant non-sulfated [3H] glucosamine-labeled molecules (likely proteoglycans) appears as smaller molecular weight peak (peak IUb, Fig. 1, C and D) after hyaluronidase treatment of void volume fractions (Fig. 1, A and B, peak Ia) from the first round of gel filtration. These studies have reproduced the typical purification schemes of large molecular weight mucus previously reported (25, 26, 28 [3H] glucosamine between CF and non-CF epithelium, we assessed the total 35S and 3H dpm counts in both crude urea dialyzed total secretions and partially purified large molecular weight glycoproteins from the first gel-filtration column (peak Ia, see Fig. 1 ). Results from this analysis are presented in Fig. 2 compared between all CF and non-CF samples the mean increase in sulfation was 1.7±0.18-fold higher (P < 0.026, n = 13) in CF as compared with non-CF samples ( Fig. 3 and Table I ). However, when the genotypes of the various CF samples were tabulated, two categories emerged which showed differences in their sulfation profile. The first of these categories involved CF samples with definable genotypes [AF508/AF508 (n = 4); AF508/1717 (n = 2); AF508/621 (n = 2); G542X/ G551D (n = 1); AF508/G542X (n = 1)] which showed a 2.0±0.15-fold higher 35S/[3H]glucosamine ratio (P < 0.004)
as compared with non-CF samples (Fig. 3) ences were seen ( Fig. 3 and Table I) . (26) while others have found no data to support this claim (30) . The etiology of differences reported between laboratories presently remains unexplained. We hypothesized that these discrepancies in the literature may be due to differences in CF genotype. Hence, using the level of mucous sulfation as a surrogate endpoint for intracellular glycoprotein processing defects, we sought to perform a comprehensive survey of mucus glycoprotein sulfation from 13 independent CF samples encompassing seven different mutant CFTR alleles. The human bronchial xenograft was chosen as the model of choice for several reasons including: (a) the absence of secondary effects caused by chronic bacterial infection, (b) its in vivo relevance as a differentiated mucociliary airway epithelium, and (c) the ability to generate genetically defined CF and non-CF airway epithelium.
The effect of airway remodeling (i.e., goblet cell hyperplasia) due to chronic bacterial infection in CF has provided the largest debated obstacle in evaluating the properties of secreted mucin and may be responsible for many of the conflicting reports evaluating primary defects. Such secondary effects of infection are thought to effect the properties of secreted and membrane bound glycoproteins. To this end, we hypothesized that culturing of CF primary airway epithelial progenitors followed by regeneration of an intact fully differentiated epithelium might provide a more "normal" distribution of airway epithelial cells. In support of this hypothesis is a recently reported study which evaluated the clonal expansion of progenitor cell clones in human bronchial xenografts using retroviral histochemical markers (33 [AF508/AF508 (n = 4); AF508/1717 (n = 2); AF508/621 (n = 2); G542X/G551D (n = 1); AF508/G542X (n = 1)]. No differences in the level of sulfation were seen within these genotypes which cumulatively demonstrated a mean increase in the 35S/[3H]glucosamine ratio of 2.0+0.15-fold (n = 10, P < 0.004). Interestingly, the CF samples which did not demonstrate an increase in sulfation had one unidentified allele [AF508/unknown (n = 2) and G551D/unknown (n = 1)]. This genotype grouping may in part explain some of the discrepancies in studying sialylation and sulfation in CF secreted mucus in the literature. All CF patients where clinically diagnosed with CF and received lung transplantation as therapy. Several clinical aspects, including age at which transplantation was performed and sweat chlorides, were compared with gain insight into the severity of disease and extent of glycoprotein processing defects. No correlation with the extent of mucous sulfation was seen with either of these two criteria. Furthermore, the extent of lung disease in all CF patients was classified as severe and implies that sulfation of mucus glycoprotein may not be pathophysiologically significant in the progression of lung disease.
The variability in mucous sulfation found between two genotypically defined groups of CF patients at present remains unexplained. However, two current hypotheses are consistent with the findings in this report. First, because of the small numbers of patients with undefined mutant allele(s) which showed no increase in sulfation, these results may be due to variability within the CF population potentially caused by modifying genes. In support of this argument is the one AF508/AF508 patient which showed no increase in the level of mucous sulfation (Table I) . This finding which demonstrates some level of variability within a defined genotype group, suggests that factor(s) not related to CFTR function may affect mucous sulfation. These factors could simply result from variability within the xenograft model system or may implicate the involvement of other genes in mucus glycoprotein processing. A second more interesting speculation may be that an as yet unidentified mutant allele( s), in the patients with partially defined genotypes, provides some level of functional intracellular CFTR capable of facilitating normal mucus glycoprotein processing. This undefined mutant allele was not found within a comprehensive screen of the 26 common CF genotypes. Despite the cause of variability in mucous sulfation between CF patients, these studies support previous findings which implicate CFTR functional involvement in mucus glycoprotein processing. The correlation of this defect with CF genotype has provided a more comprehensive look at the complexities by which CFT1R may effect this potentially pathophysiologic process.
